Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-799 pembrolizumab with chemoradiotherapy in unresectable stage III NSCLC
2018-000714-37Phase 2Unknown
- Sponsor
- Merck & Co.
- Start
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Merck & Co. Primary endpoint: Grade 3 or higher pneumonitis. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-000714-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000714-37.